Dyslipidemia and its Treatment in HIV Infection

Area of Science:

• Internal Medicine
• Infectious Diseases
• Cardiology

Background:

• HIV infection is linked to metabolic abnormalities, increasing cardiovascular disease (CVD) risk.
• Key lipid abnormalities include hypertriglyceridemia and reduced high-density lipoprotein (HDL) cholesterol, contributing to atherosclerosis.
• Antiretroviral treatments can exacerbate these metabolic issues, with risks varying by specific drug.

Purpose of the Study:

• To summarize the metabolic abnormalities and CVD risks in HIV-infected patients.
• To discuss the impact of antiretroviral therapy on lipid profiles.
• To highlight considerations for managing dyslipidemia and CVD risk in this population.

Main Methods:

• Review of metabolic abnormalities associated with HIV infection and its treatment.
• Analysis of dyslipidemia components (hypertriglyceridemia, HDL cholesterol) and atherosclerotic risk.
• Discussion of drug interactions between antiretroviral and lipid-lowering agents.

Main Results:

• HIV-infected patients exhibit significant dyslipidemia and increased CVD risk, independent of traditional factors.
• Specific antiretroviral drugs, not drug classes, are associated with adverse lipid effects.
• The relative CVD risk in HIV patients has decreased with lipid-lowering therapy, but drug interactions pose challenges.

Conclusions:

• HIV-infected individuals require careful monitoring for metabolic abnormalities and CVD risk.
• Practitioners must be aware of drug-specific metabolic risks and potential interactions when prescribing treatments.
• Managing dyslipidemia in HIV patients necessitates a nuanced approach considering both the infection and its therapies.